Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Common anti-epileptic medication shows promise in reducing migraine aura (opens in a new tab)

news-medical.net · 2026-09-25

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

Every claim we could check holds up. Three of four claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

  • 3 supported
  • 1 not covered
Open claim evidence
3
Source paper

Source layer

The 4 papers the story cites

Source study separated from background citations.

The research anchor for the report.

  • The study this story reportspresented as the new finding

    Lamotrigine prophylaxis is associated with reduced aura frequency in patients with burdensome migraine aura: a retrospective observational study

    Frontiers in Neurology · 2026

    PubMed (opens in a new tab)Full Tessa analysis (opens in a new tab)
  • The study this story reportspresented as the new finding

    Lamotrigine prophylaxis is associated with reduced aura frequency in patients with burdensome migraine aura: a retrospective observational study

    Publisher (opens in a new tab)
  • The study this story reportspresented as the new finding

    Lamotrigine prophylaxis is associated with reduced aura frequency in patients with burdensome migraine aura: a retrospective observational study

    Where the story links (opens in a new tab)
  • The study this story reportspresented as the new finding

    https://www.lunduniversity.lu.se/article/anti-epileptic-drug-may-reduce-migraine-aura

    Where the story links (opens in a new tab)
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4Not coveredThe researchers say a slower dose escalation was associated with fewer side effects, and that they are proceeding with a national randomized, double-blind, placebo-controlled trial of lamotrigine.View evidenceHide evidence

Why this verdict

The abstract-level profile includes dosing and adverse-event summaries and says further controlled evaluation is warranted, but it does not report that slower dose escalation was associated with fewer side effects, nor does it verify that a national randomized, double-blind, placebo-controlled trial is proceeding. These details may exist outside the abstract, but they are not verifiable from the supplied abstract-depth paper profile.

1

Study evidence

Lamotrigine initiation was associated with a large reduction in monthly aura days: mean MADs decreased from 6.9 ± 7.5 to 1.4 ± 3.7 days/month (79.7% mean reduction) with p < 0.001; 85.2% of patients met the predefined response threshold (≥50% reduction).Mean MADs reduced from 6.9 ± 7.5 to 1.4 ± 3.7 (79.7% mean reduction); p < 0.001; response rate 85.2% (≥50% reduction).

“A retrospective observational study was conducted at a neurology clinic in Lund, Sweden, including 81 patients treated between 2014 and 2022.”
2

Study evidence

Mean lamotrigine dose during treatment was 149.6 mg (±70.5); 29 of 81 patients experienced adverse events (most commonly skin changes), and 5 patients discontinued treatment because of adverse events.Mean dose 149.6 mg ± 70.5; 29 patients with AEs; 5 discontinuations due to AEs

“The average dose of LTG was 149.6 mg ± 70.5.”
Claim 2 of 4SupportedA new study by researchers at Lund University in Sweden found that 85 percent of patients with aura-dominant migraine experienced a reduction in monthly aura days by at least half following treatment with the anti-epileptic drug lamotrigine.View evidenceHide evidence

As stated85 percent; at least half reduction in monthly aura days

Why this verdict

The abstract-level profile reports an overall response rate of 85.2% for the predefined endpoint of at least a 50% reduction in monthly aura days after lamotrigine initiation in a retrospective Lund cohort. The story’s '85 percent' framing is quantitatively consistent. Although the claim is headline-prominent and unhedged, it is framed as a finding following treatment rather than as proven causation, and the story’s body/caveats acknowledge the retrospective uncontrolled design.

1

Study evidence

Lamotrigine initiation was associated with a large reduction in monthly aura days: mean MADs decreased from 6.9 ± 7.5 to 1.4 ± 3.7 days/month (79.7% mean reduction) with p < 0.001; 85.2% of patients met the predefined response threshold (≥50% reduction).Mean MADs reduced from 6.9 ± 7.5 to 1.4 ± 3.7 (79.7% mean reduction); p < 0.001; response rate 85.2% (≥50% reduction).

“A retrospective observational study was conducted at a neurology clinic in Lund, Sweden, including 81 patients treated between 2014 and 2022.”
Claim 3 of 4SupportedIn the study, 81 patients with frequent or particularly troublesome migraine aura were treated with lamotrigine, and the average number of aura days fell from 6.9 to 1.4 days per month, a reduction of around 80 percent.View evidenceHide evidence

As stated81 patients; 6.9 to 1.4 days per month; around 80 percent reduction

Why this verdict

The paper profile reports the same cohort size and primary quantitative result: 81 patients, mean monthly aura days decreasing from 6.9 to 1.4 after lamotrigine initiation, corresponding to a 79.7% mean reduction. The story’s 'around 80 percent' wording is accurate.

1

Study evidence

Lamotrigine initiation was associated with a large reduction in monthly aura days: mean MADs decreased from 6.9 ± 7.5 to 1.4 ± 3.7 days/month (79.7% mean reduction) with p < 0.001; 85.2% of patients met the predefined response threshold (≥50% reduction).Mean MADs reduced from 6.9 ± 7.5 to 1.4 ± 3.7 (79.7% mean reduction); p < 0.001; response rate 85.2% (≥50% reduction).

“A retrospective observational study was conducted at a neurology clinic in Lund, Sweden, including 81 patients treated between 2014 and 2022.”
Claim 4 of 4SupportedThe article says the findings need to be confirmed in a controlled study, and notes the study was retrospective and lacked a control group.View evidenceHide evidence

Why this verdict

The profile identifies the study as retrospective, observational, single-center, and without a control/comparator group, limiting causal inference. It also states that the authors recommend further evaluation in controlled trials. The story accurately reflects these caveats.

1

Study evidence

Lamotrigine initiation was associated with a large reduction in monthly aura days: mean MADs decreased from 6.9 ± 7.5 to 1.4 ± 3.7 days/month (79.7% mean reduction) with p < 0.001; 85.2% of patients met the predefined response threshold (≥50% reduction).Mean MADs reduced from 6.9 ± 7.5 to 1.4 ± 3.7 (79.7% mean reduction); p < 0.001; response rate 85.2% (≥50% reduction).

“A retrospective observational study was conducted at a neurology clinic in Lund, Sweden, including 81 patients treated between 2014 and 2022.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Other generalizability and measurement limitations: single-center clinic cohort with possible selection bias; abstract lacks detail on follow-up duration, aura-day ascertainment, missing data handling, concurrent treatments, and statistical methods.

    The story caveats mention retrospective design and lack of a control group, but do not reflect these additional abstract-profile limitations that affect interpretation and generalizability.

    From Retrospective observational cohort (single-center)

  • Safety/tolerability findings: mean lamotrigine dose was 149.6 mg ± 70.5; 29 patients had adverse events, most commonly skin changes; 5 discontinued because of adverse events.

    The story claim mentions side effects in relation to slower dose escalation, but the supplied paper profile’s material safety results are the adverse-event count, common AE type, discontinuation count, and mean dose. Those specific safety findings are not reflected in the presented story claims.

    From Retrospective observational cohort

4 things the story did carry across
  • The study was a retrospective observational single-center cohort at a neurology clinic in Lund, Sweden, including 81 lamotrigine-treated patients from 2014–2022.
  • Primary effectiveness endpoint: proportion of patients achieving at least a 50% reduction in monthly aura days after lamotrigine prophylaxis.
  • Main quantitative effectiveness result: mean monthly aura days decreased from 6.9 ± 7.5 to 1.4 ± 3.7, a 79.7% mean reduction, with an 85.2% response rate.
  • Key causal-inference limitation: retrospective pre–post design with no control/comparator group; causality cannot be established and placebo effects/regression to the mean cannot be excluded.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoAssess whether lamotrigine prophylaxis is associated with a clinically meaningful reduction in migraine aura frequency (monthly aura days) in a real-world cohort with burdensome aura.Retrospective observational cohort (single-center)Expand

In plain English

Retrospective, single-center observational cohort (n=81) of patients with burdensome migraine aura treated with lamotrigine (LTG) at a neurology clinic in Lund, Sweden (2014–2022). Primary outcome was the proportion achieving ≥50% reduction in monthly aura days (MADs) after LTG initiation. Mean MADs decreased from 6.9 ± 7.5 to 1.4 ± 3.7 days/month (79.7% mean reduction, p < 0.001); the reported overall response rate (≥50% reduction) was 85.2%. Mean LTG dose was 149.6 ± 70.5 mg. Twenty-nine patients experienced adverse events (most commonly skin changes) and 5 discontinued treatment because of adverse events. Authors conclude LTG is associated with reduced aura frequency and was generally tolerated in this clinical cohort, and recommend further evaluation in controlled trials.

Key findings

  • Lamotrigine initiation was associated with a large reduction in monthly aura days: mean MADs decreased from 6.9 ± 7.5 to 1.4 ± 3.7 days/month (79.7% mean reduction) with p < 0.001; 85.2% of patients met the predefined response threshold (≥50% reduction).Mean MADs reduced from 6.9 ± 7.5 to 1.4 ± 3.7 (79.7% mean reduction); p < 0.001; response rate 85.2% (≥50% reduction).
  • Adverse events were reported in 29 patients (most commonly skin changes); 5 patients discontinued LTG because of adverse events.
“A retrospective observational study was conducted at a neurology clinic in Lund, Sweden, including 81 patients treated between 2014 and 2022.”
What this piece can’t prove
  • Retrospective, observational, single-center design without a control or comparator group limits causal inference.
  • Abstract lacks detail on follow-up duration, methods of MAD ascertainment (e.g., diary vs recall), and handling of missing data.
  • Potential selection bias (clinic cohort of patients with burdensome aura) may limit generalizability to broader migraine populations.
  • Possible regression to the mean or placebo effects cannot be excluded in a pre–post design.

1 further detail could not be confirmed from the summary.

2human in vivoDescribe lamotrigine dosing patterns, tolerability, and adverse events (including discontinuations) during long-term management in this cohort.Retrospective observational cohortExpand

In plain English

In this retrospective clinical cohort of 81 patients treated with lamotrigine (LTG) for burdensome migraine aura, the abstract reports a mean LTG dose of 149.6 mg (±70.5). Safety reporting from clinic records identified 29 patients with adverse events (most commonly described as skin changes) and 5 patients who discontinued LTG because of adverse events.

Key findings

  • Mean lamotrigine dose during treatment was 149.6 mg (±70.5); 29 of 81 patients experienced adverse events (most commonly skin changes), and 5 patients discontinued treatment because of adverse events.Mean dose 149.6 mg ± 70.5; 29 patients with AEs; 5 discontinuations due to AEs
“The average dose of LTG was 149.6 mg ± 70.5.”
What this piece can’t prove
  • Adverse event ascertainment relied on clinical record review; the abstract does not report severity grades, onset timing, or standardized AE assessment procedures.

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 34 candidate papers

Candidate

Evaluation of the Relationship Between Crista Galli Classifications Using Cone-Beam Computed Tomography

Clinical and Experimental Health Sciences · 2026 · Crossref

Source (opens in a new tab)
CandidateOpen access

Measuring the composition and availability of human resources for health by sex in 204 countries and territories, 1990-2023, and workforce gaps for universal health coverage: a systematic analysis for the Global Burden of Disease Study 2023.

2026 · Europe PMC

Tessa (opens in a new tab)Source (opens in a new tab)

And 28 more candidates considered.